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We describe here a novel approach for detecting and quantitating human respiratory syncytial virus (RSV) based on
expression of a reporter gene from an RSV minigenome. BHK cells were cytoplasmically transformed with a noncytopathic
Sindbis virus replicon expressing T7 RNA polymerase. These cells were then cotransfected with T7 expression plasmids that
contain the cDNA of an RSV minigenome and the genes for RSV nucleocapsid proteins N, P, and L. The minigenome contains
a reporter gene such as lacZ or CAT flanked by cis-acting RSV transcription signals. Subsequent infection of these cells with
RSV resulted in a high level of reporter gene expression which could be inhibited by ribavirin. Mock-infected cells exhibited
background levels of expression. This assay can be used to quantitate RSV and titer neutralizing antibody and may be a
valuable tool for screening compounds for anti-RSV activity. It serves as a prototype for other negative-strand RNA viruses.
© 1998 Academic Press
INTRODUCTION
Human respiratory syncytial virus (RSV) is a member
of the order Mononegavirales (nonsegmented, negative-
stranded RNA genome), family Paramyxoviridae, and ge-
nus Pneumovirus (Collins et al., 1996a). RSV is the lead-
ing cause of pneumonia and bronchiolitis in infants.
Premature infants, infants with lung problems, and pa-
tients who are immunocompromised are at risk for se-
vere RSV disease. The only drug approved for treatment
of RSV is the inosine monophosphate dehydrogenase
inhibitor, ribavirin (Virazole, ICN Pharmaceuticals, Inc.,
Costa Mesa, CA) (Hall et al., 1983). A preparation of
human immune globulin (RespiGam, MedImmune, Fred-
erick, MD) has been approved for prophylaxis of RSV
disease for certain high-risk infants, but no vaccine has
been licensed to prevent RSV infection (Groothius et al.,
1993; Murphy and Collins, 1997).
Techniques for manipulating RNA virus genomes have
greatly facilitated genetic analyses of these viruses and
have enabled virologists to employ RNA viruses in ways
initially limited to DNA viruses. Construction of attenu-
ated RNA virus vaccines, use of RNA viruses as vectors
for foreign gene expression, and use of RNA viruses as
gene therapy vectors are just some of the novel applica-
tions under development. Most of the early results in this
area were accomplished with positive-strand RNA vi-
ruses (Bredenbeek and Rice, 1992; Schlesinger, 1995).
Recently a number of laboratories have described ad-
vances in the genetic manipulation of various members
of the Mononegavirales. Recovery of infectious rabies
virus, Sendai virus, vesicular stomatitis virus, measles
virus, and RSV, for example, has been accomplished by
using T7 RNA polymerase to generate full-length antige-
nomic transcripts from cDNA together with the viral pro-
teins necessary for assembly of a nucleocapsid and for
RNA replication and transcription (Schnell et al., 1994;
Collins et al., 1995; Garcin et al., 1995; Lawson et al.,
1995; Radecke et al., 1995; Whelan et al., 1995).
We thought that a variation of this strategy could be
used to develop an assay for the detection of negative-
strand RNA viruses. Our idea was to derive cell lines that
contain a reporter gene that would be expressed only
after infection with a particular RNA virus. A prototype
cell line, BHKSINLuc2, has been described for detection
of Sindbis virus, a positive-strand virus (Olivo et al., 1994).
BHKSINLuc2 cells constitutively express an RNA mole-
cule that is transcribed in the nucleus from an RNA
polymerase II promoter. This transcript is a defective
Sindbis RNA, which contains the gene for firefly lucif-
erase under the control of the Sindbis virus subgenomic
RNA promoter. Infection of BHKSINLuc2 cells with Sind-
bis virus leads to replication of this defective RNA, tran-
scription of luciferase mRNA, and high levels of lucif-
erase activity.
Recent work in a number of laboratories has defined
the cis-acting elements required for the replication and
transcription of several negative-strand virus genomes,
including RSV. This information has been used to con-
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struct synthetic analogues of genomic RNA, referred to
as minigenome RNA (Collins et al., 1991). RNA tran-
scribed from minigenome cDNA contains the cis-acting
elements necessary for replication and transcription in
RSV-infected cells and contains a reporter gene(s) in
place of viral genes. Our goal was to express such an
RSV minigenome constitutively in the cytoplasm of cells
so that infection with RSV would lead to reporter gene
expression analogous to our results with BHKSINLuc2
cells and Sindbis virus.
The most widely used cytoplasmic RNA expression
system is the vaccinia virus/T7 RNA polymerase system.
There, infection with a recombinant vaccinia virus sup-
plies intracellular T7 RNA polymerase, and the gene to
be expressed is supplied as a transfected plasmid under
the control of the T7 promoter (Fuerst et al., 1987; Elroy-
Stein and Moss, 1990). For our purposes vaccinia infec-
tion was problematic; a system that uses stably trans-
formed cells would be easier to handle and allow more
widespread use. Recently noncytopathic Sindbis virus
replicons have been developed (Frolov et al., 1996).
These replicons (SR19/pac) contain the gene for puro-
mycin resistance (pac) under control of the Sindbis sub-
genomic RNA promoter. Transfection of SR19/pac RNA
into BHK cells produces a population of puromycin-re-
sistant cells due to constitutive replication and transcrip-
tion of the noncytopathic replicon. Long-term expression
of an additional foreign gene has been achieved in cells
transformed with replicons that contain a second sub-
genomic RNA promoter (Lindenbach and Rice, 1997).
Cells that carry a replicon that expresses T7 RNA poly-
merase (SR19/T7pol/pac) can transcribe genes under
the control of the T7 promoter following transfection of
that DNA (Fig. 1A and E. Agapov et al., unpublished data).
We have investigated ways to express an RSV mini-
genome using noncytopathic Sindbis virus replicons. In
one strategy SR19/T7pol/pac-transformed cells were co-
transfected with a plasmid containing the cDNA of an
RSV minigenome downstream of a T7 promoter and
plasmids containing the genes for RSV N, P, and L pro-
teins under transcriptional control of a T7 promoter.
When the minigenome contained the lacZ gene, these
transfected cells exhibited RSV-dependent b-galactosi-
dase activity (Fig. 1). In this report we describe how such
a system can be used to quantitate RSV and how it may
be useful for titering neutralizing antibody and for
screening anti-RSV drugs.
RESULTS AND DISCUSSION
T7 RNA polymerase is functional in BHK cells that
have been transfected with SR19/T7pol/pac RNA
BHK cells electroporated with SR19/T7pol/pac RNA
were selected for puromycin resistance (Lindenbach and
Rice, 1997). To demonstrate that these cells expressed a
functional T7 RNA polymerase, we transfected them with
a plasmid (pTM1-LacZ) in which the Escherichia coli lacZ
gene is under control of a T7 promoter. Following trans-
fection of pTM1-LacZ, high levels of b-galactosidase
activity were detected in these cells, but not in control
cells that lacked the T7 RNA polymerase (Fig. 2).
BHK cells are susceptible to RSV infection and
support minigenome replication and transcription
To determine whether SR19/T7pol/pac-transfected
cells were permissive for RSV infection and minigenome
replication and expression, we transfected in vitro-syn-
thesized minigenome RNA into BHK cells that had been
infected with RSV or had been mock-infected using the
protocol described by Collins et al. for human 293 cells
(Collins et al., 1991). Only RSV-infected cells exhibited
reporter gene expression (data not shown). To determine
whether minigenome RNA transcribed in vivo in SR19/
T7pol/pac cells was functional, we adopted a protocol
analogous to that in which T7 RNA polymerase is deliv-
ered by a recombinant vaccinia virus, vTF7–3 (Grosfeld
et al., 1995). SR19/T7pol/pac cells were RSV- or mock-
infected, and immediately following infection, the cells
were transfected with a plasmid (pC2CAT) that contains
minigenome cDNA under control of a T7 promoter and
the chloramphenicol acetyltransferase (CAT) gene
flanked by RSV transcription signals (Grosfeld et al.,
1995). Under these conditions we observed a marked
increase in CAT activity in infected cells compared with
mock-infected cells (data not shown). These results in-
dicate that SR19/T7pol/pac-transformed BHK cells can
substitute for vTF7–3-infected 293 cells in experiments
that require the in vivo expression of a functional RSV
minigenome.
Preformed minigenome RNA requires RSV
nucleocapsid proteins for activity after RSV infection
Replication and transcription of RSV minigenomes are
strictly dependent on trans-acting viral proteins, whether
supplied by coinfection with standard RSV or from trans-
fected plasmids expressing RSV proteins. This sug-
gested a novel strategy whereby a minigenome could be
used to detect RSV in cell culture. Specifically, a cell line
would be prepared to constitutively express an RSV mini-
genome RNA, which contains the gene for a marker
protein that can be detected sensitively. The negative-
sense nature of the minigenome would preclude its di-
rect translation, but exposure of the cells to RSV infection
would result in the synthesis of viral proteins, thereby
complementing the replication of the RSV minigenome
and the expression of its marker gene.
To test the feasibility of this strategy, we transfected
SR19/T7pol/pac cells with the cDNA of a GFP-containing
minigenome (MP210) and 6–24 h later infected the cells
with RSV. Under these conditions, no RSV-dependent
GFP expression was observed. Under analogous condi-
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FIG. 1. The assay system for RSV-induced reporter gene expression. (A) Major components and pathways. BHK cells are transformed with a
noncytopathic Sindbis virus RNA replicon (nsP1–4*) from which are expressed the pac gene encoding puromycin N-acetyltransferase and
bacteriophage T7 DNA-dependent RNA polymerase (Lindenbach and Rice, 1997). Puromycin-resistant cells are then transfected with a plasmid
containing the cDNA of an RSV minigenome under the control of a T7 promoter and T7 expression plasmids containing the genes for the RSV
nucleocapsid proteins L, N, and P. T7 RNA polymerase-mediated transcription of the RSV minigenome in the cytoplasm is followed by cleavage of
the 39 and, for certain constructs, 59 ends, by ribozymes (E and F) that generate termini that are replication competent. Infection with RSV introduces
all the RSV gene products necessary to replicate and transcribe the minigenome. Reporter gene mRNA is translated into an easily measured enzyme
(e.g., b-galactosidase), which provides a surrogate marker of infection. (B) Major steps of the protocol. Following step 1D (puromycin selection) the
cells can be frozen and used for multiple separate transfections.
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tions in which the RSV minigenome was expressed in
vTF7–3-infected cells and subsequently infected with
RSV infection, reporter gene expression also was not
detected (P.L.C., unpublished results). This suggests that
infection with RSV is inefficient in complementing naked
minigenome RNA premade in cells. We suspect that one
factor is the very short half-life of naked intracellular
minigenome RNA, and a second factor might involve the
nonrobust nature of RSV infection in vitro.
It also has been shown that the N, P, and L proteins
are necessary and sufficient for minigenome RNA repli-
cation but that transcription of genes greater than ;1000
nt is highly inefficient unless the M2–1 protein also is
supplied (Grosfeld et al., 1995; Yu et al., 1995). More
specifically, expression of only the N and P proteins
leads to encapsidation of minigenome RNA; addition of
the L protein amplifies the amount of encapsidated mini-
genome RNA by 10- to 50-fold due to RSV-specific repli-
cation (Atreya et al., 1998) but yields little or no expres-
sion of relatively long genes such as b-galactosidase or
luciferase; and the further addition of the M2–1 protein
results in efficient marker gene expression. This sug-
gested an alternative strategy whereby a minigenome
expressed in the presence of the N, P, and L proteins
would be stabilized and amplified without significant
marker gene expression, and the subsequent introduc-
tion of viral proteins, in particular the M2–1 protein, by
RSV infection would result in efficient marker gene ex-
pression.
To test this strategy, SR19/T7pol/pac cells or SR19/pac
cells were transfected with a lacZ-containing minigenome
cDNA (pMP210LacZ) with or without pTM1-N, pTM1-P,
and pTM1-L. Six hours after transfection the cells were
trypsinized and plated in 24-well dishes and 18 h later
infected with RSV or mock-infected (Fig. 1). We observed
significant induction of b-galactosidase activity by RSV,
and the induction was dependent on expression of both
T7 RNA polymerase and the RSV nucleocapsid proteins
N, P, and L (Fig. 3A). To assess the relative requirement
for each of the nucleocapsid proteins, we transfected
various combinations of the N, P, and L expression plas-
mids. RSV-induced b-galactosidase activity was signifi-
cant only in the presence of all three nucleocapsid pro-
teins (Fig. 3B). The activity of the SR19/T7pol cells in this
assay was stable for $10 passages (data not shown).
When evaluated by histochemical staining, b-galacto-
sidase-positive infected cells were detected only in the
presence of the nucleocapsid proteins: a few stained
infected cells per well were observed with N alone or
with N plus P, but many stained infected cells were
consistently seen when N, P, and L were all expressed
(data not shown). No stained cells were observed in the
absence of RSV with or without the nucleocapsid pro-
teins. The requirement for all three nucleocapsid pro-
teins in our assay suggests that encapsidation and rep-
lication of the minigenome RNA are necessary for effi-
cient reporter gene expression by the incoming RSV. In
addition, the lack of b-galactosidase activity with the
FIG. 3. RSV-dependent b-galactosidase activity. (A) Requirement for
the nucleocapsid proteins. BHK cells transformed with a noncytopathic
Sindbis replicon that expresses T7 RNA polymerase (SR19/T7/pac) or
the parent replicon (SR19/pac) that does not express T7 RNA polymer-
ase were transfected with minigenome cDNA (1 mg of pMP210LacZ)
with or without pTM1-N, pTM1-L, and pTM1-P (0.2 mg of each). Twenty
hours after transfection the cells were trypsinized and plated into a
multiwell plate. After 6 h the cells were infected with RSV or mock-
infected, and 36 h later the cells were lysed and assayed for b-galac-
tosidase. Results shown are the means of duplicate samples. (B) The
three nucleocapsid proteins were all required for the induction of
b-galactosidase by RSV. pMP210LacZ was either transfected alone or
with various combinations of the nucleocapsid expression plasmids
(pTM1-N, pTM1-L, and pTM1-P) as indicated. Results shown are the
means of triplicate samples 6 the standard deviation.
FIG. 2. Expression of b-galactosidase in Sindbis virus replicon-
transformed cells transfected with pTM1-LacZ. BHK cells were elec-
troporated with either SR19/pac RNA or SR19/T7pol/pac RNA. Follow-
ing selection with puromycin, the cells were transfected with pTM1 or
pTM1-LacZ. Twenty-four hours later b-galactosidase activity was as-
sayed using the CPRG substrate as described under Materials and
Methods. Results shown are the means of duplicate samples.
201DETECTING RSV WITH MINIGENOME cDNA, SINDBIS VIRUS REPLICON
nucleocapsid proteins in the absence of RSV suggests
that RSV infection provides some factor(s) (e.g., M2–1
protein) necessary for transcription of lacZ mRNA (Gros-
feld et al., 1995; Collins et al., 1996b).
The level of expression of the minigenome reporter
gene is dependent on the input concentration of RSV
The assay showed a relatively linear dose-response
for RSV over a range of .1 log10 (Fig. 4A). The induced
expression exhibited a plateau effect above an inoculum
equivalent to a multiplicity of infection of ;0.6 PFU/cell
(based on HEp2 cells). These results suggest that this
assay could be used in place of a plaque assay to
quantitate RSV stocks. We also measured b-galactosi-
dase in SR19/T7pol/pac cells transfected with pMP210LacZ
as a function of time after infection following a high m.o.i.
(10 PFU/cell) or a low m.o.i. (0.2 PFU/cell). As shown in
Fig. 4B, b-galactosidase activity following a low m.o.i.
infection reached the same level as that following a high
m.o.i. infection, but with a delay of ;48 h. This suggests
that RSV replicates and spreads within the SR19/T7pol/
pac cell cultures and that the duration of an infectious
cycle is ;48 h.
RSV-induced b-galactosidase activity in SR19/T7pol/
pac cells is sensitive to ribavirin
Ribavirin inhibits in vitro replication of many RNA vi-
ruses including RSV (Sidwell et al., 1979). Depending on
the assay used, the 50% effective dose (ED50) of ribavirin
for RSV has been reported to be ;5 mg/ml (Chiba et al.,
1995). Following transfection of pMP210LacZ, pTM1-N,
pTM1-P, and pTM1-L, SR19/T7pol/pac cells were in-
fected with RSV in the presence of several concentra-
tions of ribavirin. b-Galactosidase activity was reduced
to near background levels by as little as 1 mg/ml ribavirin
(Fig. 5A). The ED50 of ribavirin was determined to be
,100 ng/ml (Fig. 5B). Treatment of the cells with ribavirin
(1 mg/ml) from the time of transfection of the RSV cDNA
plasmids until the time of RSV infection had no effect on
RSV-dependent b-galactosidase expression (data not
shown). This suggests that under the conditions this
assay was performed, ribavirin primarily affects RSV rep-
lication and transcription rather than the Sindbis replicon
or T7 polymerase transcription and that any L-protein-
mediated minigenome replication that occurs prior to
RSV replication must be relatively insensitive to ribavirin.
RSV-induced b-galactosidase activity in SR19/T7pol/
pac cells is sensitive to neutralizing antibody to RSV
RSV is a highly prevalent human pathogen, and most
adults have been infected at least once (Collins et al.,
1996a). Pooled human gamma globulin has, therefore,
significant neutralizing activity against RSV. To demon-
strate that the RSV-induced b-galactosidase activity in
this system requires infectious virus and can, therefore,
be blocked by neutralizing antibody, we incubated RSV
with a sample of pooled human gamma globulin and
then used the treated virus to infect SR19/T7pol/pac cells
that had previously been transfected with pMP210LacZ
and pTM1-N, P, and L. As shown in Fig. 6, b-galactosi-
dase activity was inversely proportional to the dilution of
the gamma globulin.
Conclusions
We have designed an assay for RSV using a noncyto-
pathic Sindbis replicon expressing the T7 RNA polymer-
ase and cDNAs for T7-mediated expression of an RSV
minigenome and the RSV nucleocapsid proteins. Our
FIG. 4. Dose-response and time course of RSV-induced expression
of b-galactosidase. Approximately 2 3 106 SR19/T7pol/pac cells in six
9.5-cm2 wells were transfected with pMP210LacZ, pTM1-N, pTM1-P,
and pTM1-L. After 18 h the transfected cells were trypsinized, pooled,
and plated into all the wells of a 48-well plate. Six hours later the cells
were infected with RSV. (A) Dose response. Approximately 105 cells
were infected with twofold dilutions of a stock of RSV (strain A2; 2 3 107
PFU/ml as titered on HEp2 cells). Results shown are means 6 SD of
triplicate samples. (B) Time course. Approximately 105 cells were in-
fected with either 0.5 ml low m.o.i.) or 25 ml high m.o.i. of the same stock
virus as in (A), and b-galactosidase activity was assayed at the indi-
cated times after infection. Note that the time scale is changed after 48
h. Results shown are the means of duplicate samples.
202 OLIVO ET AL.
studies suggest that this approach could be of value in
quantitating RSV, in screening antiviral drugs, and in
evaluating the efficacy of vaccines. As illustrated in Fig.
1A, the molecular pathways involved in this method are
complex, but, as with computer software, these complex-
ities are invisible to the user. In addition, as outlined in
Fig. 1B, the preparation of the cells requires two sepa-
rate steps (electroporation of the replicon followed by
puromycin selection and plasmid transfection), but once
the cells are prepared, the protocols for virus inoculation,
sample processing, and data readout are quite simple.
Virus activation of a reporter enzyme in genetically
modified cells has been successfully applied to a DNA
virus, a retrovirus, a positive-strand RNA virus, and, as
shown here, a negative-strand RNA virus (Felber and
Pavlakis, 1988; Rocancourt et al., 1990; Stabell and Olivo,
1992; Olivo et al., 1994; Olivo, 1996). The molecular path-
ways involved in the replication of each of these viruses
are quite different. These differences have necessitated
that the strategies used to accomplish this general ap-
proach to virus detection be tailored to each virus group.
The strategy used for each group, however, can be
viewed as a prototype for all members of that group
because it should be possible to successfully apply it to
any particular virus by incorporating virus-specific cis-
acting elements and trans-acting factors into the assay
(Olivo, 1996). Paramyxoviridae, for example, have very
similar molecular pathways of replication and transcrip-
tion; adapting our RSV method to human parainfluenza-
virus type 3 (HPIV3) could be accomplished by using T7
expression plasmids that contain HPIV3 minigenome
cDNA and the HPIV3 nucleocapsid genes (De and Ban-
erjee, 1993). As the molecular details of replication of all
pathogenic human viruses are identified, it is likely that




BHK-21 cells were obtained from ATCC. The method to
generate SR19/pac and SR19/T7pol/pac transformed
BHK cells was described previously (Lindenbach and
Rice, 1997). Human RSV (strain A2) was propagated and
titered on HEp-2 cells as described previously (Grosfeld
et al., 1995).
cDNAs
pTM1-N, pTM1-P, and pTM1-L were described in
Grosfeld et al. (1995). pTM1-LacZ was generated by
cloning the ORF of lacZ into the NcoI-BamHI window of
pTM1 (a generous gift of Bernard Moss). SR19/pac and
SR19/T7pol/pac cDNA plasmids were a generous gift of
Eugene Agapov and Charles Rice. pMP210 was made
from the C2-LUC RSV minigenome construct (Collins et
FIG. 5. Effect of ribavirin on the induction of b-galactosidase by RSV.
The experimental protocol was the same as described in Fig. 3 except
that the indicated concentrations of ribavirin were added at the time of
infection. (A) Effect of high concentrations. (B) Dose-response of sub-
inhibitory concentrations. Results shown are the means of duplicate
samples.
FIG. 6. Effect of anti-RSV neutralizing antibody on the induction of
b-galactosidase by RSV. The experimental protocol was the same as
described in Fig. 3 except that prior to infection 25 ml of RSV (titer 2 3
107 PFU/ml assayed on Hep2 cells) was incubated with the indicated
dilutions of human immune globulin at room temperature for 15 min.
Control equals incubation in the absence of antibody. Results shown
are the mean of duplicate samples.
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al., 1996a) by inserting a PCR product containing the
Green Lantern Protein gene (LifeTechnologies, Gaithes-
burg, MD) flanked by GS and GE signals into the BstXI
site in the leader and by deleting the luciferase gene and
inserting a 59 hammerhead ribozyme preceded by a
unique AvrII site (Altschuler et al., 1992). The 39 hammer-
head ribozyme was replaced with a PCR product con-
taining the antigenomic hepatitis d virus ribozyme (Per-
rotta and Been, 1991) followed by a unique XhoI site.
pMP210LacZ was made by replacing the ORF of GFP in
pMP210 with the ORF of lacZ using the unique XbaI and
XmaI sites.
Transfection protocol
All DNA transfections were performed using Lipo-
fectamine (Life Technologies, Gaithesburg, MD) accord-
ing to the manufacturer’s directions.
b-Galactosidase assay
b-Galactosidase activity of cell lysates was mea-
sured using the substrate chlorophenol red-b-D-
galactopyranoside (CPRG, Boehringer Mannheim, In-
dianapolis, IN) (final concentration 5 mM) in a 0.2 M
potassium phosphate buffer, pH 7.8, with 1 mM MgCl2.
Lysates were made in this buffer containing 1% Triton
X-100 and 1 mM dithiothreitol. Fifty microliters of ly-
sate were mixed with 50 ml of substrate in a microtiter
plate well. After incubation for 30 to 120 min at room
temperature, the optical density at a wavelength of 562
nM (OD562) was measured with a THERMOmax micro-
plate reader using SOFTmax software (Molecular De-
vices, Sunnyvale, CA). The assay was shown to be
linear up to an OD562 of 3.0.
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